{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T01:24:20Z","timestamp":1782177860878,"version":"3.54.5"},"reference-count":11,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2016,9,16]],"date-time":"2016-09-16T00:00:00Z","timestamp":1473984000000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2016,9]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Benzbromarone is a potent uricosuric but is not widely available due to concerns about hepatotoxicity. In Aotearoa New Zealand, benzbromarone has been available since April 2013, subject to funding restrictions, for patients with inadequate urate\u2010lowering response or intolerance to allopurinol and probenecid.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To assess the safety and efficacy of benzbromarone in a real\u2010life setting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>All patients who received funding for benzbromarone from 1 April 2013 to 30 September 2014 were identified. Prescribers were sent a questionnaire for each individual. Information on demographics, efficacy of previous urate\u2010lowering drugs and reasons for discontinuation were collected. Specific information about the dose, effect on serum urate, adverse effects and liver function tests after commencing benzbromarone was recorded.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Completed questionnaires were returned for 123 of 164 (75%) patients. Mean (<jats:styled-content style=\"fixed-case\">SD<\/jats:styled-content>) serum urate prior to benzbromarone was 0.57 (0.12) mmol\/L, and estimated glomerular filtration rate was 50.3 (22.8) <jats:styled-content style=\"fixed-case\">mL<\/jats:styled-content>\/min\/1.73\u2009m<jats:sup>2<\/jats:sup>. The median dose of benzbromarone was 100\u2009mg\/day (25\u2013200\u2009mg\/day). Six months after commencing benzbromarone, mean (<jats:styled-content style=\"fixed-case\">SD<\/jats:styled-content>) serum urate was 0.35 (0.12) mmol\/L. Benzbromarone\u2010related adverse events included rash (<jats:italic>n<\/jats:italic>\u2009=\u20094), diarrhoea (<jats:italic>n<\/jats:italic>\u2009=\u20099), nausea (<jats:italic>n<\/jats:italic>\u2009=\u20096) and urate stones (<jats:italic>n<\/jats:italic>\u2009=\u20093). Liver function test abnormalities were uncommon and tended to be mild. There were 14 patient deaths; none was considered related to benzbromarone. Allopurinol had been prescribed prior to benzbromarone in 117 of 123 patients; median maximum allopurinol dose was 200\u2009mg\/day (range 25\u2013600\u2009mg\/day), and 19% patients received allopurinol &gt;300\u2009mg\/day.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Benzbromarone provides useful urate\u2010lowering efficacy and does not appear unsafe in patients with gout. Urate\u2010lowering therapy prescribing requires further optimisation.<\/jats:p><\/jats:sec>","DOI":"10.1111\/imj.13173","type":"journal-article","created":{"date-parts":[[2016,7,8]],"date-time":"2016-07-08T13:28:32Z","timestamp":1467984512000},"page":"1075-1080","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["The safety and efficacy of benzbromarone in gout in Aotearoa New Zealand"],"prefix":"10.1111","volume":"46","author":[{"given":"L. K.","family":"Stamp","sequence":"first","affiliation":[{"name":"Deparment of Medicine University of Otago  Christchurch New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Haslett","sequence":"additional","affiliation":[{"name":"Deparment of Medicine University of Otago  Christchurch New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Frampton","sequence":"additional","affiliation":[{"name":"Deparment of Medicine University of Otago  Christchurch New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"White","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Waikato Hospital  Hamilton New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Gardner","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Hawkes Bay DHB  Napier New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Stebbings","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Otago  Dunedin New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Taylor","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Whanganui Hospital  Whanganui New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Grainger","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Otago  Wellington New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Taranaki Hospital  New Plymouth New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Middlemore Hospital  Auckland New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Kain","sequence":"additional","affiliation":[{"name":"Deparment of Rheumatology Tauranga Hospital  Tauranga New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Porter","sequence":"additional","affiliation":[{"name":"Nelson Hospital  Nelson New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Corkill","sequence":"additional","affiliation":[{"name":"North Shore Hospital  Auckland New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cathro","sequence":"additional","affiliation":[{"name":"Pharmaceutical Management Agency (PHARMAC)  Wellington New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Metcalfe","sequence":"additional","affiliation":[{"name":"Pharmaceutical Management Agency (PHARMAC)  Wellington New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Wyeth","sequence":"additional","affiliation":[{"name":"Pharmaceutical Management Agency (PHARMAC)  Wellington New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Dalbeth","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Auckland  Auckland New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,9,16]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature742"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00139.2009"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200831080-00002"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21772"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem056a"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.055269"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202421"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050373"},{"key":"e_1_2_7_10_1","first-page":"1646","article-title":"Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricaemia in patients with gout","volume":"33","author":"Dalbeth N","year":"2006","journal-title":"J Rheumatol"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.30119"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu157"}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fimj.13173","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imj.13173","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T08:41:27Z","timestamp":1696236087000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/imj.13173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":11,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["10.1111\/imj.13173"],"URL":"https:\/\/doi.org\/10.1111\/imj.13173","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"value":"1444-0903","type":"print"},{"value":"1445-5994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"2016-03-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-06-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-09-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}